← Patent-cliff monitor small molecule ZEPZELCA LURBINECTEDIN
Loss of exclusivity May 2040 latest FDA-listed patent expiry
Company JAZZ PHARMACEUTICALS IRELAND LTD
Drug detail Brand name ZEPZELCA Active ingredient LURBINECTEDIN Strength 4MG/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval June 2020 Marketing status RX
Listed patents Patent Expires Type 12324806 May 2040 use U-4212 12433890 May 2040 use U-4305 12440490 May 2040 use U-4252 7763615 December 2029 substance, product
Regulatory exclusivity Code Expires I-977 October 2028 ODE-304 June 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.